Clinical trials: Prostatic Disease
Prostate Cancer
Study of 2 Different Doses of Revlimid in Biochemically Relapse Prostate Cancer
The primary objectives of the study are: To evaluate feasibility, safety and tolerance of 6 months administration of Revlimid at 5mg/day and 25mg/day, given orally in subjects with prostate cancer with evidence of biochemical…
- Trial name
- NCT00348595
- Testing
- Revlimid
- Where
- United States
- Volunteers
- 77 people, healthy volunteers welcome
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Neoplasms, Prostate Cancer
Multi-Targeted Recombinant Ad5 (CEA/MUC1/Brachyury) Based Immunotherapy Vaccine Regimen in People With Advanced Cancer
Background: ETBX-011, ETBX-061, and ETBX-051 are cancer vaccines. Their goal is to teach the immune system to target and kill cancer cells. The vaccines target 3 proteins found in many types of cancer.
- Conditions
- Neoplasms, Prostate Cancer, Lung Cancer, Breast Cancer
- Trial name
- NCT03384316
- Testing
- ETBX-051; adenoviral brachyury vaccine, ETBX-061; adenoviral Mucin-1 (MUC1) vaccine, ETBX-011; adenoviral Carcinoembryonic antigen (CEA) vaccine
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- National Cancer Institute (NCI)
Prostate Cancer
RAD001 and Bicalutamide for Androgen Independent Prostate Cancer
In the treatment of castration-resistant prostate cancer (CRPC), therapies will long response durations remain elusive as a result of the inherent ability of prostate cancer cells to develop iterative resistance.
- Trial name
- NCT00630344
- Testing
- RAD001, Bicalutamide
- Where
- 2 sites in United States
- Volunteers
- 36 people
- Sponsor
- Dana-Farber Cancer Institute
Prostate Adenocarcinoma, Prostate Carcinoma
Hormone Therapy and Ipilimumab in Treating Patients With Advanced Prostate Cancer
RATIONALE: Androgens can cause the growth of prostate cancer cells. Antihormone therapy, such as leuprolide acetate, goserelin, flutamide, or bicalutamide may lessen the amount of androgens made by the body.
- Conditions
- Prostate Adenocarcinoma, Prostate Carcinoma, Recurrent Prostate Carcinoma, Stage III Prostate Cancer
- Trial name
- NCT00170157
- Testing
- Bicalutamide, Flutamide, Goserelin Acetate
- Where
- United States
- Volunteers
- 112 people
- Sponsor
- Mayo Clinic
Prostate Cancer
Ultrasound-Guided Implant Radiation Therapy in Treating Patients With Locally Recurrent Prostate Cancer Previously Treated With External-Beam Radiation Therapy
RATIONALE: Implant radiation therapy uses radioactive material placed directly into or near a tumor to kill tumor cells. PURPOSE: This phase II trial is studying the side effects and how well ultrasound-guided implant radiation…
- Trial name
- NCT00450411
- Testing
- 125-Iodine, 103-palladium
- Where
- 17 sites in United States, Canada
- Volunteers
- 100 people
- Sponsor
- Radiation Therapy Oncology Group
Prostate Cancer, Prostatic Adenocarcinoma
Androgen Deprivation Therapy Prior to Prostatectomy for Patients With Intermediate and High Risk Prostate Cancer
Degarelix is an approved drug that is used to treat prostate cancer by lowering testosterone levels in the body. Degarelix is commonly given with radiation for prostate cancer, but less frequently with surgery since there has…
- Trial name
- NCT01542021
- Testing
- degarelix injection, androgen deprivation therapy
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Metastatic Prostate Cancer
Expanded Access to Diagnostic Imaging for Staging of Recurrent Prostate Cancer
This Phase 3 study will target approximately 100 men over age 18 who have a biochemical relapse or other evidence of relapse of prostate cancer after primary treatment. The purpose of this study is to: A.
- Trial name
- NCT02260817
- Testing
- 11C-choline Injection
- Where
- United States
- Volunteers
- 109 people
- Sponsor
- Global Isotopes, LLC d/b/a Zevacor Molecular
Prostate Cancer
Provenge With or Without pTVG-HP DNA Booster Vaccine in Prostate Cancer
This randomized pilot clinical trial studies sipuleucel-T with or without deoxyribonucleic acid (DNA) vaccine therapy in treating patients with prostate cancer that has not responded to previous treatment with hormones and has…
- Trial name
- NCT01706458
- Testing
- sipuleucel-T, DNA Vaccine
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- University of Wisconsin, Madison
Healthy
Novel 13C Carotenoids for Absorption and Metabolism Studies in Humans
Tomatoes contain several compounds which may be beneficial for human health and prevention of disease, although this relationship is poorly understood and very controversial.
- Trial name
- NCT01692340
- Testing
- Isotopically labeled lycopene, phytoene or phytofluene
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Ohio State University Comprehensive Cancer Center
Prostate Cancer
Genomic Guided Therapy With Dasatinib or Nilutamide in Metastatic Castration-Resistant Prostate Cancer
This is a phase II multi-center study to determine the clinical impact of using a patient-specific genomic expression signature of androgen receptor (AR) activity to determine therapy for patients with castration-resistant…
- Trial name
- ARS (NCT00918385)
- Testing
- Nilutamide, Dasatinib
- Where
- 3 sites in United States
- Volunteers
- 57 people
- Sponsor
- Duke University
Prostate Cancer
A Degarelix Trial in Patients With Prostate Cancer
A phase III extension trial comparing the efficacy and safety of degarelix 3 month depot with the established therapy Zoladex 3 month implant in patients with prostate cancer.
- Trial name
- NCT01242748
- Testing
- Degarelix, Goserelin acetate
- Where
- 63 sites in United States, Belgium and 11 more
- Volunteers
- 288 people
- Sponsor
- Ferring Pharmaceuticals
Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma
Sirolimus, Docetaxel, and Carboplatin in Treating Patients With Metastatic Castration-Resistant Prostate Cancer
This partially randomized phase I/II trial studies the side effects and how well sirolimus works when given together with docetaxel and carboplatin in treating patients with castration-resistant prostate cancer that has spread to…
- Conditions
- Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma, Stage IV Prostate Cancer AJCC v7, Metastatic Malignant Neoplasm in the Bone
- Trial name
- NCT02565901
- Testing
- Carboplatin, Docetaxel, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- University of Washington
Prostate Cancer
Treatment With Radiolabeled Monoclonal Antibody HuJ591-GS (177Lu-J591) in Patients With Metastatic Prostate Cancer
The purpose of this study is to find out how effective 177Lu -J591 is in the treatment of patients with metastatic, androgen-independent prostate cancer.
- Trial name
- NCT00195039
- Testing
- 177Lu Radiolabeled Monoclonal Antibody HuJ591 (177Lu -J591)
- Where
- United States
- Volunteers
- 47 people
- Sponsor
- Weill Medical College of Cornell University
Prostate Cancer
Study to Assess the Efficacy of Brachytherapy With or Without Hormone Therapy, Using Triptorelin 22.5mg in Patients With Recurrence of Prostate Cancer
The primary objective of the study was to compare the efficacy of brachytherapy versus brachytherapy + triptorelin 22.5 mg (single injection) in subjects with recurrence of prostate cancer previously treated with radiotherapy.
- Trial name
- ANABRAQ (NCT01374087)
- Testing
- Triptorelin 22.5 mg, Brachytherapy
- Where
- 11 sites in Spain
- Volunteers
- 32 people
- Sponsor
- Ipsen
Prostate Cancer, Elevated PSA
A Prospective, Randomized Trial Comparing Office-based MR-guided Prostate Biopsy Approaches
This randomized trial will compare the safety and efficacy of TPM versus TRUS biopsies performed in the outpatient setting. Primary endpoints will be pain as well as detection of clinically significant disease (defined as Gleason…
- Trial name
- NCT03632655
- Testing
- prostate biopsy
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- Weill Medical College of Cornell University
Prostate Cancer
Prostate Cancer - Patient Empowerment Program
Each year over 20,000 men are diagnosed with prostate cancer in Canada with the majority undergoing some form of treatment option.
- Trial name
- PC-PEP (NCT03660085)
- Testing
- PC-PEP
- Where
- Canada
- Volunteers
- 140 people, healthy volunteers welcome
- Sponsor
- Nova Scotia Health Authority
Prostatic Neoplasms, Neoplasm Metastasis
Aflibercept in Combination With Docetaxel in Metastatic Androgen Independent Prostate Cancer
Primary objective was to demonstrate overall survival improvement with aflibercept compared to placebo in patients receiving docetaxel / prednisone for metastatic androgen-independent prostate cancer (MAIPC).
- Trial name
- VENICE (NCT00519285)
- Testing
- Aflibercept, Docetaxel, Prednisone or Prednisolone
- Where
- 31 sites in United States, Argentina and 29 more
- Volunteers
- 1,224 people
- Sponsor
- Sanofi
Solid Tumors
Avelumab in Metastatic or Locally Advanced Solid Tumors (JAVELIN Solid Tumor)
This is a Phase 1, open-label, dose-escalation trial of avelumab [antibody targeting programmed death ligand 1 (anti PD-L1)] with consecutive parallel group expansion in participants with selected tumor indications.
- Trial name
- NCT01772004
- Testing
- Avelumab
- Where
- 74 sites in United States, Belgium and 7 more
- Volunteers
- 1,756 people
- Sponsor
- EMD Serono Research & Development Institute, Inc.
Prostate Cancer
Urology San Antonio MRI/MicroUS Comparison
This study compares micro-ultrasound image targeted prostate biopsy with multi-parametric MRI targeted biopsy in men indicated for prostate biopsy due to suspicion of prostate cancer.
- Trial name
- NCT03762616
- Testing
- Micro-ultrasound targeted biopsy, mpMRI targeted biopsy
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- Exact Imaging
Cushing's Disease, Acromegaly
Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in Novartis-sponsored Studies
The purpose of this study is to allow continued use of pasireotide in patients who are on pasireotide treatment in a Novartis-sponsored study and are benefiting from the treatment as judged by the investigator.
- Conditions
- Cushing's Disease, Acromegaly, Neuroendocrine Tumors, Pituitary Tumors
- Trial name
- NCT01794793
- Testing
- Pasireotide, Cabergoline, Pasireotide LAR
- Where
- 94 sites in United States, Argentina and 26 more
- Volunteers
- 337 people
- Sponsor
- RECORDATI GROUP
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.